AD)		

Award Number: W81XWH-06-1-0323

TITLE: Checkpoint Functions of the BRCA1/BARD1 Tumor Suppressor

PRINCIPAL INVESTIGATOR: Ami Modi

CONTRACTING ORGANIZATION: Columbia University

New York, NY 10032

REPORT DATE: July 2007

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 1. REPORT DATE 2. REPORT TYPE

valid OMB control number. PL			RESS.		
1. REPORT DATE		2. REPORT TYPE			ATES COVERED
01-07-2007		Annual Summary			ıl 2006 – 30 Jun 2007
4. TITLE AND SUBTIT	LE			5a. 0	CONTRACT NUMBER
Checkpoint Functions of the BRCA1/BARD1 Tumor Supp			pressor	W8	GRANT NUMBER 1XWH-06-1-0323 PROGRAM ELEMENT NUMBER
=					
6. AUTHOR(S)				5d. I	PROJECT NUMBER
Ami Modi				5e. 1	TASK NUMBER
				5f. V	VORK UNIT NUMBER
Email: am2338@co					
7. PERFORMING ORG	SANIZATION NAME(S)	AND ADDRESS(ES)		-	ERFORMING ORGANIZATION REPORT
				N.	UMBER
Columbia Universi	ty				
New York, NY 100	32				
9 SPONSOPING / MO	NITODING AGENCY N	AME(S) AND ADDRESS	S/ES)	10.9	SPONSOR/MONITOR'S ACRONYM(S)
	Research and Mat		3(L3)	10. \	or creation and a remaining)
		lenei Command			
Fort Detrick, Maryl	and 21/02-5012				
					SPONSOR/MONITOR'S REPORT
				1	NUMBER(S)
12 DISTRIBUTION / A	VAILABILITY STATEM	IFNT			
IL. DIGITADO HOITA	· · · · · · · · · · · · · · · · · · ·				
	c Release; Distribu				
Approved for Publi	c Release; Distribu				
	c Release; Distribu				
Approved for Publi	c Release; Distribu				
Approved for Publi	c Release; Distribu				
Approved for Publi 13. SUPPLEMENTARY 14. ABSTRACT	c Release; Distribu	tion Unlimited			
13. SUPPLEMENTARY 14. ABSTRACT The breast and ovari	c Release; Distribu r NOTES ian-specific tumor sup	tion Unlimited			rocesses, including DNA repair, cell
13. SUPPLEMENTARY 14. ABSTRACT The breast and ovaricycle checkpoint con	c Release; Distribu Y NOTES tan-specific tumor supertrol, and mitotic spino	ppressor BRCA1 has belie assembly. <i>In vivo</i> ,	BRCA1 primarily exis	ts in association	with BARD1 and the BRCA1/BARD1
13. SUPPLEMENTARY 14. ABSTRACT The breast and ovaricycle checkpoint conheterodimer is though	r NOTES Tan-specific tumor supertrol, and mitotic spinor to mediate the tum	opressor BRCA1 has to the assembly. <i>In vivo</i> , nor suppression activity	BRCA1 primarily exis y of BRCA1. It has be	ts in association en previously sh	with BARD1 and the BRCA1/BARD1 own that the phosphorylation state of
13. SUPPLEMENTARY 14. ABSTRACT The breast and ovaricycle checkpoint conheterodimer is thoughthe BARD1 polypept	r NOTES an-specific tumor supertrol, and mitotic spinor ht to mediate the tumide is cell cycle regular.	opressor BRCA1 has be the assembly. <i>In vivo</i> , nor suppression activity ated and that BARD1	BRCA1 primarily exis y of BRCA1. It has be is hyperphosphorylate	ts in association en previously sho d in mitosis at se	with BARD1 and the BRCA1/BARD1 own that the phosphorylation state of even distinct residues. To study the
13. SUPPLEMENTARY 14. ABSTRACT The breast and ovaricycle checkpoint conheterodimer is thoughthe BARD1 polypept function of mitotic BARD1 polypept function	r NOTES ian-specific tumor supertrol, and mitotic spinor ht to mediate the tumide is cell cycle regula ARD1 phosphorylatior	opressor BRCA1 has be the assembly. <i>In vivo</i> , nor suppression activity ated and that BARD1 in, I used an siRNA-me	BRCA1 primarily exis y of BRCA1. It has be is hyperphosphorylate ediated approach to kr	ts in association en previously sho d in mitosis at so lockdown endog	with BARD1 and the BRCA1/BARD1 own that the phosphorylation state of even distinct residues. To study the enous BARD1 expression and then
13. SUPPLEMENTARY 14. ABSTRACT The breast and ovaricycle checkpoint conheterodimer is thoughthe BARD1 polypept function of mitotic BA restore expression was a supplemental or a supplemental o	r NOTES ian-specific tumor supertrol, and mitotic spinor ht to mediate the tumide is cell cycle regular ARD1 phosphorylation with siRNA-resistant experience.	opressor BRCA1 has be alle assembly. In vivo, nor suppression activity ated and that BARD1 in, I used an siRNA-meakogenous forms of BA	BRCA1 primarily exis y of BRCA1. It has be is hyperphosphorylate ediated approach to kr ARD1. In this manner,	ts in association en previously sho d in mitosis at so lockdown endog I will evaluate th	with BARD1 and the BRCA1/BARD1 own that the phosphorylation state of even distinct residues. To study the enous BARD1 expression and then he role of BARD1 mitotic
13. SUPPLEMENTARY 14. ABSTRACT The breast and ovaricycle checkpoint conheterodimer is thoughthe BARD1 polypept function of mitotic BA restore expression with a phosphorylation in the supplementary of the supplementary	r NOTES an-specific tumor supertrol, and mitotic spinor ht to mediate the tumide is cell cycle regula ARD1 phosphorylation with siRNA-resistant ene G2 accumulation c	ppressor BRCA1 has been been been been been been been bee	BRCA1 primarily exis y of BRCA1. It has be is hyperphosphorylate ediated approach to kr ARD1. In this manner, on checkpoint, and ho	ts in association en previously shad in mitosis at so lockdown endog I will evaluate the mology-directed	with BARD1 and the BRCA1/BARD1 own that the phosphorylation state of even distinct residues. To study the enous BARD1 expression and then he role of BARD1 mitotic DNA repair. My initial studies showed
13. SUPPLEMENTARY 14. ABSTRACT The breast and ovaricycle checkpoint conheterodimer is thoughthe BARD1 polypept function of mitotic BA restore expression with a phosphorylation in the that siRNA-mediated.	r NOTES Tan-specific tumor supertrol, and mitotic spinor ht to mediate the tumide is cell cycle regular ARD1 phosphorylation with siRNA-resistant ene G2 accumulation coll knockdown of BARD	opressor BRCA1 has be assembly. In vivo, nor suppression activity ated and that BARD1 in, I used an siRNA-me axogenous forms of BA heckpoint, decatenation leads to a consideration.	BRCA1 primarily exis y of BRCA1. It has be is hyperphosphorylate ediated approach to kr ARD1. In this manner, on checkpoint, and ho able IR-induced G2 ac	ts in association en previously should in mitosis at selected will evaluate the mology-directed ecumulation checken.	with BARD1 and the BRCA1/BARD1 own that the phosphorylation state of even distinct residues. To study the enous BARD1 expression and then he role of BARD1 mitotic DNA repair. My initial studies showed expoint defect, illustrated by an ~8-fold
13. SUPPLEMENTARY 14. ABSTRACT The breast and ovaricycle checkpoint conheterodimer is thoughthe BARD1 polypept function of mitotic BA restore expression with a phosphorylation in the that siRNA-mediated increase in the percentage.	r NOTES An-specific tumor supertrol, and mitotic spinor ht to mediate the tumide is cell cycle regular ARD1 phosphorylation with siRNA-resistant energy accumulation cell knockdown of BARD ant of cells that entergrants.	ppressor BRCA1 has be assembly. In vivo, or suppression activity ated and that BARD1 in, I used an siRNA-me exogenous forms of BA heckpoint, decatenation leads to a consider mitosis following IR da	BRCA1 primarily exis y of BRCA1. It has be- is hyperphosphorylate ediated approach to kr ARD1. In this manner, on checkpoint, and ho able IR-induced G2 ac amage relative to conti	ts in association ten previously should in mitosis at selected will evaluate the mology-directed coumulation chected colos. Reconstant	with BARD1 and the BRCA1/BARD1 own that the phosphorylation state of even distinct residues. To study the enous BARD1 expression and then he role of BARD1 mitotic DNA repair. My initial studies showed expoint defect, illustrated by an ~8-fold estitution experiments with mRNAs
13. SUPPLEMENTARY 14. ABSTRACT The breast and ovaricycle checkpoint conheterodimer is thoughthe BARD1 polypept function of mitotic BA restore expression with a siRNA-mediated increase in the percensistant to knockdown	r NOTES An-specific tumor supertrol, and mitotic spinor hit to mediate the tumide is cell cycle regular ARD1 phosphorylation with siRNA-resistant energy accumulation of knockdown of BARD ent of cells that enter with by BARD1-specific	ppressor BRCA1 has been been been been been been been bee	BRCA1 primarily exis y of BRCA1. It has begin is hyperphosphorylate adiated approach to know the begin is approach to know the begin is approach to know the begin is a property of the	ts in association en previously shed in mitosis at selected will evaluate the mology-directed cumulation chected cells. Reconserverselected as a selected experience of cells.	with BARD1 and the BRCA1/BARD1 own that the phosphorylation state of even distinct residues. To study the enous BARD1 expression and then he role of BARD1 mitotic DNA repair. My initial studies showed expoint defect, illustrated by an ~8-fold stitution experiments with mRNAs cells that escape the IR-induced G2
13. SUPPLEMENTARY 14. ABSTRACT The breast and ovaricycle checkpoint conheterodimer is thoughthe BARD1 polypept function of mitotic BA restore expression with a siRNA-mediated increase in the percentage of the	r NOTES an-specific tumor supertrol, and mitotic spinor hit to mediate the tumide is cell cycle regulary phosphorylation with siRNA-resistant energy accumulation of knockdown of BARD ent of cells that enter with by BARD1-specific point. We are current	ppressor BRCA1 has been been been been been been been bee	BRCA1 primarily exis y of BRCA1. It has being is hyperphosphorylate adiated approach to knaRD1. In this manner, on checkpoint, and hoable IR-induced G2 act amage relative to controlled dividual phosphorylati	ts in association an previously should in mitosis at some cockdown endog I will evaluate the mology-directed cumulation checked col cells. Reconse percentage of on sites in the clean previously in t	with BARD1 and the BRCA1/BARD1 own that the phosphorylation state of even distinct residues. To study the enous BARD1 expression and then he role of BARD1 mitotic DNA repair. My initial studies showed expoint defect, illustrated by an ~8-fold stitution experiments with mRNAs cells that escape the IR-induced G2 heckpoint by reconstituting BARD1-
13. SUPPLEMENTARY 14. ABSTRACT The breast and ovaricycle checkpoint conheterodimer is thoughthe BARD1 polypept function of mitotic BA restore expression with a siRNA-mediated increase in the percentage of the	r NOTES an-specific tumor supertrol, and mitotic spinor hit to mediate the tumide is cell cycle regulary phosphorylation with siRNA-resistant energy accumulation of knockdown of BARD ent of cells that enter with by BARD1-specific point. We are current	ppressor BRCA1 has been been been been been been been bee	BRCA1 primarily exis y of BRCA1. It has begin is hyperphosphorylate adiated approach to know the begin is approach to know the begin is approach to know the begin is a property of the	ts in association an previously should in mitosis at some cockdown endog I will evaluate the mology-directed cumulation checked col cells. Reconse percentage of on sites in the clean previously in t	with BARD1 and the BRCA1/BARD1 own that the phosphorylation state of even distinct residues. To study the enous BARD1 expression and then he role of BARD1 mitotic DNA repair. My initial studies showed expoint defect, illustrated by an ~8-fold stitution experiments with mRNAs cells that escape the IR-induced G2 heckpoint by reconstituting BARD1-
13. SUPPLEMENTARY 14. ABSTRACT The breast and ovaricycle checkpoint conheterodimer is thoughthe BARD1 polypept function of mitotic BA restore expression with a siRNA-mediated increase in the percentage of the	r NOTES an-specific tumor supertrol, and mitotic spinor hit to mediate the tumide is cell cycle regulary phosphorylation with siRNA-resistant energy accumulation of knockdown of BARD ent of cells that enter with by BARD1-specific point. We are current	ppressor BRCA1 has been been been been been been been bee	BRCA1 primarily exis y of BRCA1. It has being is hyperphosphorylate adiated approach to knaRD1. In this manner, on checkpoint, and hoable IR-induced G2 act amage relative to controlled dividual phosphorylati	ts in association an previously should in mitosis at some cockdown endog I will evaluate the mology-directed cumulation checked col cells. Reconse percentage of on sites in the clean previously in t	with BARD1 and the BRCA1/BARD1 own that the phosphorylation state of even distinct residues. To study the enous BARD1 expression and then he role of BARD1 mitotic DNA repair. My initial studies showed expoint defect, illustrated by an ~8-fold stitution experiments with mRNAs cells that escape the IR-induced G2 heckpoint by reconstituting BARD1-
13. SUPPLEMENTARY 14. ABSTRACT The breast and ovaricycle checkpoint conheterodimer is thoughthe BARD1 polypept function of mitotic BA restore expression with a siRNA-mediated increase in the percentage of the	c Release; Distribute Release; Distribute Release; Distribute Release; Distribute Release; Distribute Release	ppressor BRCA1 has been been been been been been been bee	BRCA1 primarily exis y of BRCA1. It has being is hyperphosphorylate adiated approach to knaRD1. In this manner, on checkpoint, and hoable IR-induced G2 act amage relative to controlled dividual phosphorylati	ts in association an previously should in mitosis at some cockdown endog I will evaluate the mology-directed cumulation checked col cells. Reconse percentage of on sites in the clean previously in t	with BARD1 and the BRCA1/BARD1 own that the phosphorylation state of even distinct residues. To study the enous BARD1 expression and then he role of BARD1 mitotic DNA repair. My initial studies showed expoint defect, illustrated by an ~8-fold stitution experiments with mRNAs cells that escape the IR-induced G2 heckpoint by reconstituting BARD1-
14. ABSTRACT The breast and ovaricycle checkpoint conheterodimer is thoughthe BARD1 polypept function of mitotic BArestore expression with phosphorylation in the that siRNA-mediated increase in the percentage i	c Release; Distribute Release; Distribute Release; Distribute Release; Distribute Release; Distribute Release	ppressor BRCA1 has be assembly. In vivo, for suppression activity ated and that BARD1 and that BARD1 are acceptable to a consider mitosis following IR data as iRNAs resulted in a ly testing the role of in 1 polypeptides bearing	BRCA1 primarily exis y of BRCA1. It has being is hyperphosphorylate adiated approach to knaRD1. In this manner, on checkpoint, and hoable IR-induced G2 act amage relative to controlled dividual phosphorylati	ts in association an previously should in mitosis at some cockdown endog I will evaluate the mology-directed cumulation checked col cells. Reconse percentage of on sites in the clean previously in t	with BARD1 and the BRCA1/BARD1 own that the phosphorylation state of even distinct residues. To study the enous BARD1 expression and then he role of BARD1 mitotic DNA repair. My initial studies showed expoint defect, illustrated by an ~8-fold stitution experiments with mRNAs cells that escape the IR-induced G2 heckpoint by reconstituting BARD1-
14. ABSTRACT The breast and ovaricycle checkpoint conheterodimer is thoughthe BARD1 polypept function of mitotic BArestore expression with phosphorylation in the that siRNA-mediated increase in the percentage i	r NOTES fan-specific tumor supertrol, and mitotic spinor ht to mediate the tumide is cell cycle regular ARD1 phosphorylation with siRNA-resistant ener G2 accumulation cell knockdown of BARD ent of cells that enter who by BARD1-specific point. We are current RNA-resistant BARD	ppressor BRCA1 has be assembly. In vivo, for suppression activity ated and that BARD1 and that BARD1 are acceptable to a consider mitosis following IR data as iRNAs resulted in a ly testing the role of in 1 polypeptides bearing	BRCA1 primarily exis y of BRCA1. It has being is hyperphosphorylate adiated approach to knaRD1. In this manner, on checkpoint, and hoable IR-induced G2 act amage relative to controlled dividual phosphorylati	ts in association an previously should in mitosis at some cockdown endog I will evaluate the mology-directed cumulation checked col cells. Reconse percentage of on sites in the clean previously in t	with BARD1 and the BRCA1/BARD1 own that the phosphorylation state of even distinct residues. To study the enous BARD1 expression and then he role of BARD1 mitotic DNA repair. My initial studies showed expoint defect, illustrated by an ~8-fold stitution experiments with mRNAs cells that escape the IR-induced G2 heckpoint by reconstituting BARD1-
14. ABSTRACT The breast and ovaricycle checkpoint conheterodimer is thoughthe BARD1 polypept function of mitotic BArestore expression with that siRNA-mediated increase in the percensistant to knockdown accumulation checkpidepleted cells with sirest BARD1; BRCA1;	r NOTES Jan-specific tumor supertrol, and mitotic spinor ht to mediate the tumide is cell cycle regular ARD1 phosphorylation crith siRNA-resistant energy and the specific spinor. We are current if RNA-resistant BARD siRNA; DNA dama	ppressor BRCA1 has be assembly. In vivo, for suppression activity ated and that BARD1 and that BARD1 are acceptable to a consider mitosis following IR data as iRNAs resulted in a ly testing the role of in 1 polypeptides bearing	BRCA1 primarily exis y of BRCA1. It has being be	ts in association on previously should in mitosis at selected will evaluate the mology-directed ecumulation check on sites in the class phosphorylation	with BARD1 and the BRCA1/BARD1 own that the phosphorylation state of even distinct residues. To study the enous BARD1 expression and then he role of BARD1 mitotic DNA repair. My initial studies showed expoint defect, illustrated by an ~8-fold stitution experiments with mRNAs cells that escape the IR-induced G2 heckpoint by reconstituting BARD1-n sites.
14. ABSTRACT The breast and ovaricycle checkpoint conheterodimer is thoughthe BARD1 polypept function of mitotic BArestore expression with phosphorylation in the that siRNA-mediated increase in the percentage i	r NOTES Jan-specific tumor supertrol, and mitotic spinor ht to mediate the tumide is cell cycle regular ARD1 phosphorylation crith siRNA-resistant energy and the specific spinor. We are current if RNA-resistant BARD siRNA; DNA dama	ppressor BRCA1 has be assembly. In vivo, for suppression activity ated and that BARD1 and that BARD1 are acceptable to a consider mitosis following IR data as iRNAs resulted in a ly testing the role of in 1 polypeptides bearing	BRCA1 primarily exis y of BRCA1. It has being be	ts in association on previously should be previously should be provided in mitosis at some provided and the provided become and the provided become percentage of the prosphorylation o	with BARD1 and the BRCA1/BARD1 own that the phosphorylation state of even distinct residues. To study the enous BARD1 expression and then he role of BARD1 mitotic DNA repair. My initial studies showed expoint defect, illustrated by an ~8-fold stitution experiments with mRNAs cells that escape the IR-induced G2 heckpoint by reconstituting BARD1-n sites.
14. ABSTRACT The breast and ovaricycle checkpoint conheterodimer is thoughthe BARD1 polypept function of mitotic BA restore expression with phosphorylation in the that siRNA-mediated increase in the percensistant to knockdown accumulation checkpdepleted cells with simple BARD1; BRCA1; 16. SECURITY CLASS	r NOTES Jan-specific tumor supertrol, and mitotic spinor hit to mediate the tumide is cell cycle regular ARD1 phosphorylation critical sirandary in the sirand	opressor BRCA1 has be assembly. In vivo, nor suppression activity ated and that BARD1 in, I used an siRNA-mexogenous forms of BA heckpoint, decatenation and the sire of the s	BRCA1 primarily exis y of BRCA1. It has being be	ts in association on previously should in mitosis at selected will evaluate the mology-directed ecumulation check on sites in the class phosphorylation	with BARD1 and the BRCA1/BARD1 own that the phosphorylation state of even distinct residues. To study the enous BARD1 expression and then he role of BARD1 mitotic DNA repair. My initial studies showed expoint defect, illustrated by an ~8-fold stitution experiments with mRNAs cells that escape the IR-induced G2 heckpoint by reconstituting BARD1-n sites. 19a. NAME OF RESPONSIBLE PERSON USAMRMC
14. ABSTRACT The breast and ovaricycle checkpoint conheterodimer is thoughthe BARD1 polypept function of mitotic BArestore expression with that siRNA-mediated increase in the percensistant to knockdown accumulation checkpidepleted cells with sirest BARD1; BRCA1;	r NOTES Jan-specific tumor supertrol, and mitotic spinor ht to mediate the tumide is cell cycle regular ARD1 phosphorylation crith siRNA-resistant energy and the specific spinor. We are current if RNA-resistant BARD siRNA; DNA dama	ppressor BRCA1 has be assembly. In vivo, for suppression activity ated and that BARD1 and that BARD1 are acceptable to a consider mitosis following IR data as iRNAs resulted in a ly testing the role of in 1 polypeptides bearing	BRCA1 primarily exis y of BRCA1. It has being be	ts in association on previously should be previously should be provided in mitosis at some provided and the provided become and the provided become percentage of the prosphorylation o	with BARD1 and the BRCA1/BARD1 own that the phosphorylation state of even distinct residues. To study the enous BARD1 expression and then he role of BARD1 mitotic DNA repair. My initial studies showed expoint defect, illustrated by an ~8-fold stitution experiments with mRNAs cells that escape the IR-induced G2 heckpoint by reconstituting BARD1-n sites.

Table of Contents

	<u>Page</u>
Introduction	5
Body	5
Key Research Accomplishments	6
Reportable Outcomes	6
Conclusion	7
References	7
Appendices	none

Introduction: The objective of my research is to determine the role of BARD1 phosphorylation in the checkpoint functions of the BRCA1/BARD1 heterodimer [1]. In my original application, I proposed to achieve this by generating and characterizing isogenic subclones of HCT116 cells that express different knock-in alleles of BARD1. In the past year, however, I also tested the feasibility of an alternative approach based siRNA-mediated depletion of endogenous BARD1 coupled to transient reconstitution with exogenous BARD1. This approach has several clear advantages over the original knock-in strategy. First, since it involves transient transfection of a cell population, this approach is not susceptible to artifacts that arise due to clonal variation. Second, unlike the knock-in strategy, which is restricted to certain pseudo-diploid cell lines such as HCT116, this approach can be applied to a broad range of cell types. Third, this approach is more facile since it does not require the laborious process of generating stable knock-in subclones by targeted gene recombination.

Body: To implement this approach, I first designed two distinct siRNAs (siRNAs A and B) that can greatly reduce endogenous BARD1 expression (>90%) in a variety of cell lines. Second, by site-directed mutagenesis I introduced noncoding mutations into our BARD1 mammalian expression plasmids that render the resultant mRNAs resistant to knockdown by either siRNA A or B. With these reagents, we should be able to test whether BARD1 phosphorylation is required for specific checkpoint functions of BRCA1. For example, a BRCA1-dependent function, such as the IR-induced G₂ accumulation checkpoint, should be ablated by siRNA-mediated BARD1 knockdown, either as a direct consequence of BARD1 inactivation or as an indirect consequence of BRCA1 instability in the absence of BARD1. In either case, transfection of the siRNA-treated cells with a siRNA-resistant vector encoding wildtype BARD1 should rescue the checkpoint. If, however, a specific phosphorylation site (for example, S251) is required for the G₂ accumulation checkpoint, then transfection with a siRNA-resistant vector encoding S251A-mutant BARD1 should restore the expression levels of BRCA1 but not rescue checkpoint activity. Thus, by reconstituting siRNA-treated cells with siRNA-resistant expression vectors encoding the full panel of wildtype and phosphorylation site mutant BARD1 polypeptides, we should be able to identify the precise requirements for BARD1 phosphorylation in checkpoint function. A similar strategy was used successfully by Yu et al. to demonstrate a requirement for BACH1 phosphorylation in the same IR-induced G₂ accumulation checkpoint [2]; thus, we will be able to use BACH1 siRNAs and siRNA-resistant BACH1 expression plasmids kindly provided by Dr. Junjie Chen as reliable controls for analysis of the G₂ accumulation checkpoint [2]. Moreover, this strategy can be used not only to study the G₂ accumulation checkpoint (as proposed in Task 1), but also the IR-induced mitotic exit checkpoint (Task 2) and other BRCA1dependent functions, such as the decatenation checkpoint and HDR-mediated double-strand DNA break repair.

Key Research Accomplishments: Two different BARD1-specific siRNAs (A and B) were designed to have a GC content of 30-50% and a general sequence of AA(19N)TT targeting the coding region of BARD1 mRNA. The chemically synthesized RNA duplexes were also created to have 3' overhanging UU dinucleotides, since these are reported to be most effective in knocking down the intended target [3]. The target sequence of siRNA A lies in coding exons 2/3 of BARD1, while that of siRNA B resides in coding exon 9. siRNA-mediated knockdowns were conducted by transient transfection of 293 cells with HiPerfect (Qiagen), a reagent that allows for highly effective gene silencing at low siRNA concentrations that minimize off-target effects. In pilot experiments, we observed that two sequential siRNA transfections (8 nM), approximately 24 hours apart, yields a highly effective knockdown (>90%) of BARD1 with either the A or B siRNAs, as compared to cells treated with the non-targeting (negative control) siRNA. The knockdown efficiencies were monitored at both 48 hrs and 72 hrs post-second transfection by Western analysis.

Reportable Outcomes: In evaluating the effect of BARD1 knockdown on the G2 accumulation checkpoint, siRNA-mediated knockdown of BRCA1 was included as a positive control, since BRCA1 is known to be required for this checkpoint [2]. Approximately 48 hrs and 72 hrs post-second transfection, one set of cells was irradiated with 10 Gy, while a second set was mock treated. After three hours at 37°C, both treated and mock-treated cells were incubated for 15 hours with nocodazole (1ug/mL) to arrest cells in mitosis. The cells were then fixed with 70% ethanol and placed at -20°C overnight. The mitotic population of each culture was then measured by flow cytometric analysis after staining with propidium iodide and the mitotic marker, phospho-histone H3. As expected, knockdown of BRCA1 caused a defect in activation of the G2 accumulation checkpoint. Significantly, BARD1 knockdown also induced a checkpoint defect, as illustrated by an ~8-fold increase in the percentage of cells that entered mitosis following IR treatment relative to control cells.

To confirm that the observed checkpoint defect is due to BARD1 knockdown, and not to non-specific off-target effects of the siRNAs, we introduced silent mutations into the siRNA-specific targeting regions of a BARD1 mammalian expression vector to render its mRNA product resistant to either the BARD1-specific siRNA A or B. Two mutations, especially if placed together near the middle of the siRNA sequence, are generally sufficient to ablate siRNA-mediated knockdown, although more mutations can only help [3]. In our design of siRNA-resistant BARD1 expression vectors, we were able to introduce 3 or 4 tandem nucleotide changes that disrupted siRNA complementarity but did not alter the coding potential of the vector. Of note, the BARD1 polypeptides encoded by these vectors contain an N-terminal tag of three tandem FLAG epitopes that allows the endogenous and exogenous (i.e., vector-encoded) forms of BARD1 to be distinguished in rescue experiments. To ascertain whether the G2 accumulation checkpoint of the BARD1 siRNA-treated cells is due to BARD1

depletion, 293 cells that had been BARD1-depleted by two successive siRNA transfections (with siRNAs A or B) were transiently co-transfected with the appropriate siRNA-resistant BARD1 expression vector. Western blot analysis with a FLAG-specific antibody confirmed successful expression of exogenous BARD1 in siRNA-treated cells. Significantly, these cells displayed an ~ 3-fold decrease in the percentage of mitotic cells after IR exposure, indicating that reconstitution of BARD1-depleted cells with siRNA-resistant wildtype BARD1 provides a partial rescue of the G2 accumulation checkpoint.

The results described here were recently reported as an abstract at the Annual Meeting of the American Association of Cancer Research in April, 2007 [4].

Conclusion: With this system of BARD1 rescue in place, we are now in a position to test the role of individual BARD1 phosphorylation sites in this checkpoint by reconstituting BARD1-depleted cells with siRNA-resistant BARD1 polypeptides bearing defined mutations of specific phosphorylation sites. This approach will be used in the coming year to determine whether specific BARD1 phosphorylation events are required for BRCA1-dependent processes, such as the G2 accumulation checkpoint.

References:

- 1. Choudhury, A.D., H. Xu, A.P. Modi, W. Zhang, T. Ludwig, and R. Baer (2005). Hyperphosphorylation of the BARD1 tumor suppressor in mitotic cells. J. Biol. Chem. 280: 24669-24679.
- 2. Yu, X., C.C. Chini, M. He, G. Mer, and J. Chen (2003). *The BRCT domain is a phospho-protein binding domain.* Science 302: 639-642.
- 3. Elbashir, S.M., J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl (2001). *Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.* Nature 411: 494-498.
- Modi, A.P., A.D. Choudhury, and R. Baer (2007). Functional Analysis of Mitotic Phosphorylations in BARD1. American Association for Cancer Research (AACR) Annual Meeting (April 2007; Los Angeles, CA).